Back to Search
Start Over
Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab.
- Source :
-
JAAD case reports [JAAD Case Rep] 2022 Dec 28; Vol. 32, pp. 109-112. Date of Electronic Publication: 2022 Dec 28 (Print Publication: 2023). - Publication Year :
- 2022
-
Abstract
- Competing Interests: Dr Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, 10.13039/100002429Amgen, Aralez, 10.13039/100018748ArgenX, 10.13039/100004325AstraZeneca, 10.13039/100012431Celldex, Centogene, 10.13039/100008322CSL Behring, 10.13039/100016525FAES, 10.13039/100004328Genentech, GIInnovation, 10.13039/100004330GSK, Innate Pharma, 10.13039/501100004095Kyowa Kirin, 10.13039/501100023331Leo Pharma, 10.13039/100004312Lilly, Menarini, Moxie, 10.13039/100004336Novartis, 10.13039/100004319Pfizer, 10.13039/100004337Roche, Sanofi/Regeneron, Third Harmonic Bio, 10.13039/100011110UCB, and Uriach. Drs Zhu, Fok, Lin, and Su have no conflicts of interest to declare.
Details
- Language :
- English
- ISSN :
- 2352-5126
- Volume :
- 32
- Database :
- MEDLINE
- Journal :
- JAAD case reports
- Publication Type :
- Report
- Accession number :
- 36712834
- Full Text :
- https://doi.org/10.1016/j.jdcr.2022.12.009